**2.4 Colombia**

Colombia has a national PID referral center located in University of Antioquia in Medellin, which has laboratory equipped to perform molecular and immunological diagnosis of PID, and other centers and programs are being developed in Bogota, Cali, Cartagena and Barranquila. Currently, 80% of cases of PID in Colombia come from Antioquia (Montoya *et al.,* 2002; Obando *et al.,* 2005) and neighboring states, which represents less than 20% of Colombia population. Most clinical laboratories in Colombia are able to perform initial PID screening, but specific tests are only available in Medellin and Bogota (Montoya *et al.,* 2002; Diaz *et al.,* 2008). In Colombia, the government Compulsory Health Plan (POS) provides basic coverage for PID and additional coverage can be obtained from private insurance companies (Gonzáles *et al.,* 1999; Cardona & Segura, 2011). Patients with PID, who need IVIG, are not refunded by POS, but IVIG treatments are covered by private insurance companies, who refunded through government's national fund FOSYGA. In this country there is Foundation for Diana Garcia de Olarte PID, which supports and develops educational programs, provides infrastructure for IVIG treatment centers and offers legal advice for patients who need IVIG (Montoya & Sorensen, 2001). The University of Antioquia in Medellin has immunology program for medical residents, and like Latin American countries, this prefer specialize in other areas, since the financial return is greater (Condino-Neto *et al.,* 2011).

### **2.5 Honduras**

Honduras has two PID diagnostic centers, located in Tegucigalpa and San Pedro Sula, accessible to entire community, first laboratory support specific PID, and country have serious problems in laboratory diagnosis and access costs (Leon, 2003), availability of IVIG and cost. Only two hospitals in Tecigalpa, including National Institute of Social Security, provide treatment with IVIG. The country has no specific PID program residency, and receives training only three months on basic immunology, autoimmunity, allergy and immunodeficiency (Condino-Neto *et al.,* 2011).
